Fulcrum Therapeutics (FULC) Income from Continuing Operations: 2020-2025
Historic Income from Continuing Operations for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' Income from Continuing Operations rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Income from Continuing Operations stood at -$19.6 million for Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
- Fulcrum Therapeutics' Income from Continuing Operations' 5-year high stood at $55.4 million during Q2 2024, with a 5-year trough of -$34.1 million in Q2 2022.
- For the 3-year period, Fulcrum Therapeutics' Income from Continuing Operations averaged around -$14.4 million, with its median value being -$22.7 million (2023).
- Per our database at Business Quant, Fulcrum Therapeutics' Income from Continuing Operations spiked by 332.98% in 2024 and then tumbled by 131.86% in 2025.
- Fulcrum Therapeutics' Income from Continuing Operations (Quarterly) stood at -$23.5 million in 2021, then fell by 11.29% to -$26.1 million in 2022, then rose by 5.28% to -$24.8 million in 2023, then soared by 33.07% to -$16.6 million in 2024, then climbed by 9.68% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.7 million for Q2 2025, and -$16.6 million during Q4 2024.